Literature DB >> 10443932

The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury.

P S Ray1, G Maulik, G A Cordis, A A Bertelli, A Bertelli, D K Das.   

Abstract

The consumption of red wine has been reported to impart a greater benefit in the prevention of coronary heart disease than the consumption of other alcoholic beverages. This beneficial effect is increasingly being attributed to certain antioxidants comprising the polyphenol fraction of red wine such as transresveratrol. In the present study, we investigated the potential cardioprotective effects of resveratrol in the face of ischemia reperfusion (I/R) injury. Isolated perfused working rat hearts after stabilization were perfused with Krebs-Henseleit Bicarbonate buffer (KHB) either in the presence or absence of transresveratrol (RVT) at a concentration of 10 microM for 15 min prior to subjecting them to 30 min of global ischemia followed by 2 h of reperfusion. Left ventricular functions were monitored at various timepoints throughout the reperfusion period to assess the extent of postischemic recovery in comparison with baseline values. Coronary perfusate samples were also collected to determine malonaldehyde (MDA) levels. The results demonstrated that RVT exhibited significant myocardial protection. This was evidenced by improved recovery of post-ischemic ventricular function including developed pressure and aortic flow as compared to the control group (KHB). Values for developed pressure in the RVT-treated group were significantly higher than those in the control group throughout the reperfusion period (71.09+/-4.88 mm Hg vs. 58.47+/-3.88 mm Hg, 68.87+/-5.07 mm Hg vs. 49.74+/-2.65 mm Hg and 51.67+/-3.95 mm Hg vs. 30.50+/-4.80 mm Hg at reperfusion timepoints R-15, R-60, and R-120, respectively). From R-30 onwards, aortic flow was markedly higher in the RVT treated group as compared with the control group, the differences being most significant at R-90 (32.45+/-2.19 ml/min vs. 19.83+/-1.62 ml/min) and R-120 (27.15+/-2.27 ml/min vs. 14.10+/-1.69 ml/min). In contrast to the KHB treated group, the RVT-treated group displayed significant reduction in MDA formation especially in the immediate early reperfusion period (63.71+/-8.19 pM/ml vs. 130.86+/-4.76 pM/ml, 63.84+/-15.62 pM/ml vs. 156.99+/-18.93 pM/ml, 71.29+/-2.80 pM/ml vs. 129.5+/-10.30 pM/ml and 56.25+/-5.79 pM/ml vs. 127.99+/-3.50 pM/ml at timepoints R-1, R-3, R-5, and R-7, respectively) indicating a reduction in I/R injury related oxidative stress. Infarct size was markedly reduced in the RVT group when compared with the control group (10.57+/-0.35% vs. 36.27+/-5.28%). In vitro studies revealed RVT to be a potent scavenger of peroxyl radicals suggestive of a probable mechanism involved in the protective ability of RVT. The results of this study indicate that resveratrol possesses cardioprotective effects which may be attributed to its peroxyl radical scavenging activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443932     DOI: 10.1016/s0891-5849(99)00063-5

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  70 in total

1.  The effect of Euryale ferox (Makhana), an herb of aquatic origin, on myocardial ischemic reperfusion injury.

Authors:  Samarjit Das; Peter Der; Utpal Raychaudhuri; Nilanjana Maulik; Dipak K Das
Journal:  Mol Cell Biochem       Date:  2006-04-21       Impact factor: 3.396

Review 2.  Resveratrol and resveratrol analogues--structure-activity relationship.

Authors:  Thomas Szekeres; Monika Fritzer-Szekeres; Philipp Saiko; Walter Jäger
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

3.  Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites.

Authors:  Juma Hoshino; Eun-Jung Park; Tamara P Kondratyuk; Laura Marler; John M Pezzuto; Richard B van Breemen; Shunyan Mo; Yongchao Li; Mark Cushman
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

4.  Inhibition of Na⁺-H⁺ exchange as a mechanism of rapid cardioprotection by resveratrol.

Authors:  Luong Cong Thuc; Yasushi Teshima; Naohiko Takahashi; Satoru Nishio; Akira Fukui; Osamu Kume; Shotaro Saito; Mikiko Nakagawa; Tetsunori Saikawa
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes.

Authors:  Matteo Becatti; Niccolò Taddei; Cristina Cecchi; Niccolò Nassi; Paolo Antonio Nassi; Claudia Fiorillo
Journal:  Cell Mol Life Sci       Date:  2012-02-05       Impact factor: 9.261

6.  Grape seed extract acting on astrocytes reveals neuronal protection against oxidative stress via interleukin-6-mediated mechanisms.

Authors:  Kayoko Fujishita; Tetsuro Ozawa; Keisuke Shibata; Shihori Tanabe; Yoji Sato; Masashi Hisamoto; Tohru Okuda; Schuichi Koizumi
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

7.  Experimental evidence for the cardioprotective effects of red wine.

Authors:  Samarjit Das; Dev D Santani; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2007

Review 8.  Resveratrol and the eye: activity and molecular mechanisms.

Authors:  Christina Bola; Hannah Bartlett; Frank Eperjesi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-21       Impact factor: 3.117

9.  Ethanol preconditioning protects against ischemia/reperfusion-induced brain damage: role of NADPH oxidase-derived ROS.

Authors:  Qun Wang; Albert Y Sun; Agnes Simonyi; Theodore J Kalogeris; Dennis K Miller; Grace Y Sun; Ronald J Korthuis
Journal:  Free Radic Biol Med       Date:  2007-07-04       Impact factor: 7.376

10.  Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation.

Authors:  Mahmood Khan; Iyyapu K Mohan; Vijay K Kutala; Sainath R Kotha; Narasimham L Parinandi; Robert L Hamlin; Periannan Kuppusamy
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.